New developments and future directions in the management of systemic lupus erythematosus. (PubMed, Curr Opin Immunol) - Apr 15, 2026 - "Nevertheless, since the 2011 Food and Drug Administration (FDA) approval of belimumab for SLE, there has been an explosion of clinical trials that has led to the approval of anifrolumab for SLE as well as belimumab, voclosporin, and obinutuzumab for lupus nephritis. At the same time, multiple drugs with important new targets have progressed through phase 1-3 clinical trials, promising improved outcomes. In this review, we focus on new and emerging treatments over the last few years and discuss their potential impact on developing new directions in lupus management."
Journal • Review • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus
|
|
Kyriakos A Kirou; Raphael A Kirou; Sofia Flouda
|